| 
 
 
  
    
 
  
     | 
    
The
      Foundation for Chiropractic 
      Education and Research
     | 
   
 
  
Thanks to FCER for permission to reproduce this article! 
Response to Meta-Analysis Published By Assendelft Et Al 
By
      Anthony L. Rosner, Ph.D., LL.D. (Hon.) 
      June 25, 2003
  
      
      The recent meta-analysis by Assendelft et al., published in the
      June 3, 2003 edition of the Annals of Internal Medicine  [1] 
      is a troubling example of how clinical data is to be interpreted and
      presented for public consumption and policy development. In addition to
      raising numerous issues as to the clinical applicability of meta-analyses,
      it may even belie its basic premises as will be pointed out below. In
      reviewing this document, one must remain vigilant as to how the rowdy
      qualities of human bias, subjectivity, and disagreement extend well into
      the rarefied atmospheres of randomized clinical trials, meta-analyses, and
      actual clinical guidelines.
  
      The overall conclusion of this report—that there is no evidence that
      spinal manipulation therapy is superior to either standard treatments for
      patients with acute or chronic low back pain—can be interpreted in the
      same breath to indicate that, in terms of the pain or disability outcomes
      scales evaluated, it is neither inferior. Before one analyzes the
      methodological issues of the report itself, one is entirely justified to
      ask whether the treatments are truly equivalent.
  
                  1.      Comparative Side Effects and Relative Safety:   
  
      For spinal manipulation, the occurrence of major complications
      (regardless of the region of the spine manipulated) has generally been
      shown to be less than one per million.  [2–5]  Even transient, minor
      side-effects have been estimated to occur at 1 per 120,000 cervical
      manipulations.  [6]  These figures pale when compared to an
      extensive body of literature describing as many as 220,000 deaths and
      other complications produced in the United States each year by medications
      in general  [7–14]  or the 10,000–20,000 fatalities and multiple
      organ systems adversely affected by NSAIDs.  [15–23]  Even what has
      been regarded as the more relatively benign COX-2 inhibitors  [24–27] 
      and acetaminophen medications  [28]  have been described to generate
      serious GI, cardiovascular, and hepatic problems at rates orders of
      magnitude greater than side-effects attributed to spinal manipulation. The
      overall picture comparing spinal manipulation to the commonly used
      treatment alternatives of either direct analgesic ingestion or visits to
      the general practitioner (80% resulting in analgesic use by the authors’
      own citation  [1, 29] ) should be one of relative clarity to the
      patient: In one instance there is an option with a low rate of lasting
      side-effects and in the other a treatment regimen with severe and
      sometimes fatal complications that are inexplicably deemed to be
      "acceptable."  [30] 
  
                  2.      Mix of Clinical Judgment with Data from the Literature:  
  
      The authors strongly imply that this study is intended to be more
      rigorous than the systematic reviews and meta-analyses that preceded it.
      Yet their admission to the effect that the comparison of spinal
      manipulative therapy with each different treatment alternative for each
      outcome for each back pain stratum "was not possible because the data
      were sparse" raises one’s suspicion that this particular review may
      not have been as "systematic" as first presumed. These fears are
      confirmed in the very next sentence which informs the reader that the
      clinical judgment of effectiveness benchmarks from members of the
      Cochrane Editorial Board was used to fill in the gaps of experimental
      data, undermining the very process championed in this study. Indeed, the
      noted epidemiologist David Sackett applauds the use of clinical expertise
      as well as experimental outcomes data to build a truly effective evidence
      base for optimum patient care,  [31]  a sentiment echoed elsewhere
      as well.  [32]  But this undercuts the very process that the authors
      suggest that they are undertaking in pursuit of the most definitive
      experimental data available. In other words, how much adulteration of this
      "systematic review" has taken place?
  
                  3.      Inadmissible Criterion of Quality:  
  
      One of the criteria for methodologic quality of RCTs by the Cochrane
      Group—the blinding of the care provider (V3)—is impossible in the
      administration of manual therapy, particularly high-velocity spinal
      manipulation. Accordingly, its inclusion by the authors as a determinant
      of inclusion or rejection of RCTs is without justification. As many as 11
      studies have erroneously reported double-blinding in the chiropractic
      experimental literature; the nonfeasibility of blinding the practitioner
      in numerous modalities of alternative medicine has been extensively
      discussed elsewhere and needs to be duly noted.  [33] 
  
            4.      Guideline Rationale:  
  
      As part of their rationale for embarking upon this investigation,
      Assendelft et al. bemoan the disparity of recommendations for spinal
      manipulative therapy from different countries, citing in particular the
      dissension expressed in the guidelines from Australia, Israel, and The
      Netherlands. What the authors do not disclose is the preponderance of
      support for spinal manipulation expressed in 8 out of a total of 11 such
      guidelines, with perhaps an additional half thrown in for The Netherlands
      (which found sufficient justification for treating acute but not chronic
      back pain by spinal manipulation,  [34]  an oddity since van Tulder
      [who is Dutch] decisively supported the chronic over the acute evidence in
      a recent systematic review).  [35]  Furthermore, in the comparison
      of guidelines cited by the authors, there was concordance among all
      11 nations (United States, United Kingdom, The Netherlands, Israel, New
      Zealand, Finland, Australia, Switzerland, Germany, Denmark, and Sweden) in
      six aspects of healthcare: (i) diagnostic triage, history taking, and
      physical examination; (ii) their conclusion that radiographs were not
      useful for managing nonspecific low back pain; (iii) their recognition of
      the importance of psychosocial factors; (iv) their discouragement of bed
      rest; (v) certain stipulations regarding the prescription of medications;
      and (vi) their concluding that the vast majority of low back pain cases
      should be managed in a primary care setting. Other areas besides spinal
      manipulation in which differences arose were (i) exercise therapy,
      (ii) muscle relaxants, and (iii) patient information.
  
      The reason this census of nations regarding guideline and medical
      practices has been taken is to point out that the reported concordances
      and discordances do not appear to correlate with the amount, design, and
      quality of randomized clinical trials or systematic literature reviews
      that have been published. Rather, there appear to be human and cultural
      values at work here that I would maintain have not necessarily been
      eliminated in the study currently under discussion. This leads directly to
      our next point of critique.
  
            5.      Meta-Analyses Themselves Are Subject to Bias and Omissions:  
  
      Regarding their clinical relevance, the very basis of meta-analyses
      (including the report of Assendelft et al.) has to be closely scrutinized.
      One report has gone so far as to compare meta-analyses to statistical
      alchemy, due to their intrinsic nature:
         
          "...the removal and destruction of the scientific requirements
          that have been so carefully developed and established during the 19th
          and 20th centuries. In the mixtures formed for most statistical
          meta-analyses, we lose or eliminate the elemental scientific
          requirements for reproducibility and precision, for suitable
          extrapolation, and even sometimes for fair comparison."  [36]
         
 
Specifically, Feinstein raises the following deficiencies of meta-analyses, most having to do with the sloughing of
      important clinical information:
         
i.      Disparate groups of
          patients of varying homogeneity across different studies are thrown
          into one analysis, often called a "mixed salad";
  
ii.      The weighting of
          studies of different quality may be inaccurate or absent altogether;
  
iii.      One needs to know
          about the real-world effects in the presentation and treatment of
          patients; in particular
(a) the severity of the illness,  
(b) co-morbidities,  
(c) pertinent co-therapies, and  
(d) clinically relevant and meaningful outcomes;
 
 
iv.      Inconsistent
          statistical techniques pertaining to increments, effect size,
          correlation coefficients, and relative risk and odds ratios;
  
v.      Omission of the
          reference denominator; and
  
vi.      The fact that the odds ratio inflates the
          true value of the relative risk under certain conditions.
 
         
 
      In any event, the numbers of patients needed to treat must be
      reported in order to observe a true difference in treatment groups, a
      practice often overlooked in meta-analyses.  [36]  To make matters
      worse, a recent report involving four medical areas (cardiovascular
      disease, infectious disease, pediatrics, and surgery) indicates that
      individual quality measures were not reliably associated with the strength
      of the treatment effect in 276 RCTs analyzed in 26 meta-analyses.  [37] 
  
      The fact that arbitrariness and bias can not only creep into but
      actually dominate in meta-analyses is both convincingly and
      dramatically demonstrated in a recent publication in the Journal of the
      American Medical Association. In their efforts to compare two
      different preparations of heparin for their respective abilities to
      prevent post-operative thrombosis, Juni and his colleagues have revealed
      that diametrically opposing results can be obtained in different
      meta-analyses, depending upon which of 25 scales is used to distinguish
      between high- and low-quality RCTs. The root of the problem is evident
      from the variability of weights given to three prominent features of RCTs
      (randomization, blinding, and withdrawals) by the 25 studies which have
      compared the two therapeutic agents. In one investigation, for example, a
      third of the total weighting of the quality of the trial is afforded to
      both randomization and blinding, whereas in another, none of the
      quality scoring is derived from these two features. Widely skewed
      intermediate values for the three aspects of RCTs under discussion are
      apparent from the 23 other scales presented. The astute reader will
      immediately suspect that sharply conflicting conclusions might be drawn
      from these different studies—and these fears are amply borne out by the
      forest plot presented in the study. Here each of the meta-analyses listed
      resolve the studies they have reviewed into high- and low-quality strata,
      based upon each of their scoring systems. It can be seen that ten of the
      studies selected show a statistically superior effect of one heparin
      preparation over the other, but only for the low-quality studies.
      Seven other studies reveal precisely the opposite effect, in which
      the high- but not the low-quality studies display a statistically
      significant superiority of low-molecular weight heparin. Depending upon
      which scale one uses, therefore, one can either demonstrate or refute the
      clinical superiority of one clinical treatment over the other. In this
      manner, therefore, all the rigor and labor-intensive elements of the RCT
      and its interpretation by the meta-analysis are simply reduced to the
      subjective and undoubtedly capricious human element of value judgment
      through the arbitrary assignment of numbers in the weighting of
      experimental quality.  [38]  Reduced to lay terms often used to
      describe the limits of computer capabilities, one might summarize this
      undertaking as an apt demonstration of the principle, "Garbage in,
      garbage out."
  
                  6.      Contradictions in Design:  
  
There appear to be contradictions in the
      design in the authors’ comparison of spinal manipulative therapy to 7
      other treatment therapies (sham, conventional general practitioner,
      analgesics, physical therapy, exercises, back school, or collection of
      therapies judged to be ineffective or even harmful [traction, corset, bed
      rest, home care, topical gel, no treatment, diathermy, or minimal
      massage]). Specifically:
       
        
a.      Conventional general
          practitioner and analgesic use is considered to be synonymous,
          based upon a single reference which suggests that 80% of visits to the
          general practitioner result in a prescription for using an analgesic.
          Why then, should analgesic use then be presented in the report as a
          discrete intervention?
  
b.      Physical therapy is stated to
          include exercise in amounts up to 100%. Again, why should exercise
          then be presented elsewhere as a separate intervention?
  
          
       
        7. Contradictions in Evaluating Statistical and Clinical Significance:  
  
      One especially troubling situation arises with the authors’
      interpretation of the forest plots comparing spinal manipulative and sham
      therapies. In one instance (Figure 3), spinal manipulative therapy is
      shown to have "clinically important" short-term improvements in
      pain and disability; however, these differences are deemed to have
      "failed to reach a conventional level of statistical
      significance." In comparing spinal manipulative therapy to the group
      of treatments deemed ineffective, however, we now find a statistically
      significant advantage for the former intervention. It is perplexing indeed
      to then find the authors stating that "the clinical significance
      of this finding is questionable (italics mine)."  [1]  In
      the very simplest of terms, one cannot have it both ways. It would almost
      seem as if there were a deliberate effort to minimize a treatment effect
      of potential interpret pertaining to spinal manipulation.
  
                  8.      Data are Not Shown in Areas of Interest:  
   
      Given the aforementioned arbitrary characteristics of meta-analyses and
      perhaps of the authors’ presentation as well, one has every reason to
      wish for the opportunity to examine the data which support the authors’
      contention that "our sensitivity analyses supported the robustness of
      our results with respect to the type of manipulative therapy, profession
      of the manipulator, and the quality of the studies included."  [1] 
      However, none pertaining to these critical areas were presented in the
      body of the paper. The issue is particularly important with regard to the
      skill and training of the manipulator, who at times has been
      misrepresented in the scientific literature.  [39, 40]  It is
      questionable how effectively the authors were able to draw comparisons of
      different chiropractic techniques, as they overlooked the most recent and
      arguably comprehensive attempts to do so from both the points of view of
      clinical effectiveness  [41]  and a literature review.  [42] 
  
                  9.      Clinical as Opposed to Fastidious Treatments:  
  
      Some treatments (traction, diathermy, minimal massage) have been deemed
      by the authors to lack sufficient evidence for their effectiveness as
      stand-alone applications, and as such have been rejected from
      consideration in this investigation. What is not clear, however, is
      whether they are effective in a synergistic manner as ancillary
      treatments and whether they have been excluded as potentially helpful
      adjuncts to manual therapy. This was alluded to in Feinstein’s
      discussion of meta-analyses presented above (critique #5).  [36] 
  
                  10.      Lack of Long-Term Followup:  
  
      Followups for back pain outcome assessments are limited in this study
      to 6 months. However, numerous studies cite recurrences of low back pain
      for up to 1 year.  [43–45]  This not only makes the definition of an
      episode problematical,  [46]  but it demands that follow-up times
      for at least a year be observed in order to assess a more durable and
      perhaps economical treatment effect. Indeed, the longevity of treatment
      effects of spinal manipulation in managing back pain for 12 months  [47–49] 
      to 3 years  [50]  have been amply demonstrated. In comparison to
      medications for the treatment of headaches, it has been shown to be
      markedly superior.  [51, 52]  As in several aforementioned areas of
      this study, this particular aspect for comparing treatments might be
      expected to diminish the actual capacity of spinal manipulation to display
      its full benefits.
  
                  CONCLUDING REMARKS  
  
      From a variety of perspectives, this meta-analyses appears to be both
      flawed and to have either obscured or overlooked the maximal clinical
      benefits that might be expected to have been conferred upon patients by
      spinal manipulation, particularly as performed by a chiropractor. The
      patient response to intervention is far more complex than the dimensions
      offered by the authors in their discussion. Tonelli points out, for
      example, that there will always be a region in which discrete differences
      between individuals cannot be made explicit and quantified, called an
      epistemological zone.  [53]  This degree of sophistication is best
      summarized by Horwitz, who points out that to assume that the entire range
      of clinical treatment in any modality has been successfully captured by
      the precision of existing analytical methods in the scientific literature
      "would be like saying that a medical librarian who has access to
      systematic reviews, meta-analyses, Medline, and practice guidelines
      provides the same quality of healthcare as an experienced physician."  [54] 
      Hopefully, these shortcomings in the current meta-analyses can be
      appreciated by the public and addressed more meaningfully in future
      research.
 
  
        
      REFERENCES:
       1   Assendelft
      WJJ, Morton SC, Yu EI, Suttorp MJ, Shekelle PG.  
Spinal manipulative therapy for low back pain: A meta-analysis of effectiveness relative to
      other therapies.  
Annals of Internal Medicine 2003; 138: 871-881.
  
       2   Haldeman
      S, Rubinstein SM.  
Cauda equina syndrome in patients undergoing manipulation of the lumbar spine.  
Spine 1992; 17(12): 1469-1473.
  
       
3   Terrett
      AGL, Kleynhans AM.  
Complications from manipulations of the low back.  
Chiropractic
      Journal of Australia 1992; 22(4): 129-140.
  
       
4   Hurwitz EL, Aker PO, Adams AH, Meeker WC, Shekelle PG.  
Manipulation and Mobilization of the Cervical Spine: 
A Systematic Review of the Literature  
Spine (Phila Pa 1976) 1996 (Aug 1); 21 (15): 1746–1760
  
       
5   Haldeman
      S, Carey P, Townsend M, Papadopoulos C.  
Arterial Dissections Following Cervical Manipulation: The Chiropractic Experience 
Canadian Medical Association Journal 2001 ( Oct 2);     165 (7):   905–906
  
       
6   Klougart N, Leboeuf-Yde C, Rasmussen LR.  
Safety in Chiropractic Practice Part II: Treatment to the Upper Neck 
and the Rate of Cerebrovascular Incidents  
J Manipulative Physiol Ther 1996 (Nov);    19 (9):    563–569
  
       
7   Lazarou
      J, Pomeranz B, Corey P.  
Incidence of adverse drug reactions in hospitalized patients.  
Journal of the American Medical Association 1998;
      279(15): 1200-1205.
  
       
8   Phillips
      D, Christenfeld N, Glynn L.  
Increase in US medication-error deaths between 1983 and 1993.  
Lancet 351: 643-644.
  
       
9   Schuster
      M, McGlynn E. Brook R.  
How good is the quality of health care in the United States?  
Milbank Quarterly 1998; 76: 517-563.
  
       
10   Weingart
      SN, Wilson RM, Gibberd RW, Harrison B.  
Epidemiology and medical error.  
British  Medical Journal 2000; 320: 774-777.
  
       
11   Starfield
      B.  
Is US health really the best in the world?  
Journal of the American
      Medical Association 2000; 284(4): 483-485.
  
       
12   Report from the Inspector General of the Department of Health and Human Services; 
      Lauran Neergard, Associated Press, December 15, 1999.
  
       
13   Gandhi
      TK, Weingart SN, Borus J, Seger AC, Peterson J, Burdick E, Seger DL, Shu
      K, Federico F  
Adverse drug events in ambulatory care. 
      New England Journal of Medicine 2003; 348(16): 1556-1564.
  
       
14   Gurwitz
      JH, Field TS, Harrold LR, Rothschild J, Debellis K, Seger AC, Cadoret C,
      Fish LS, Garber L  
Incidence and preventability of adverse drug events among older persons in the ambulatory setting.  
Journal
      of the American Medical Association 2003; 289(9): 1107-1116.
  
       
15   Wolfe
      MM, Lichtenstein DR, Singh G.  
Gastrointestinal Toxicity of Nonsteroidal Anti-inflammatory Drugs  
New England Journal of Medicine 1999 (Jun 17);   340 (24):   1888–99 
  
       
16   Ament
      PW, Childers RS  
Prophylaxis and treatment of NSAID-induced gastropathy.  
American
      Family Physician 1997; 55(4): 1323-1326, 1331-1332.
  
       
17   Simon
      LS. Osteoarthritis: An overview.  
Clinical Cornerstone 1999; 2(2):
      26-34.
  
       
18   Fries
      JF.  
Assessing and understanding patient risk.  
Scandinavian Journal of
      Rheumatology 1992; 92(Suppl): 21-24.
  
       
19   Armstrong
      CP, Blower AL.  
Non-steroidal anti-inflammatory drugs and life-threatening complications of peptic ulceration.  
Gut 1987; 28: 527-532.
  
       
20   Gabriel
      SE, Jaakkimainen L, Bombardier C.  
Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs:
      A meta-analysis.  
Annals of Internal Medicine 1991; 115: 787-796.
  
       
21   Carson
      JL, Willett LR.  
Toxicity of nonsteroidal anti-inflammatory drugs: An overview of the epidemiological evidence.  
Drugs 1993; 46(Suppl 1):
      243-248.
  
       
22   Carson
      JL, Strom BL, Soper KA, West SL, Morse SL.  
The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding.  
Archives
      of Internal Medicine 1987; 147: 85-88.
  
       
23   Page
      J, Henry D.  
Consumption of NSAIDS and the development of congestive heart failure in elderly patients.  
Archives of Internal Medicine 2000;
      160: 777-784.
  
       
24   Bombardier
      C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz
      MB, Hawkey CJ.  
Comparison of upper gastrointestinal toxicity of Rofecoxib and naproxen in patients with
      rheumatoid arthritis. VIGOR Study Group.  
New England Journal of
      Medicine 2000; 343: 1520-1528.
  
       
25   Important
      drug safety information: Vioxx (Dear Healthcare Professional Letter). 
      Point-Claire, Dorval (QC): Merck Frosst Canada; 2002 April 15. Available: 
      www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/advisory/industry/vioxx_e.html 
      (accessed 2002 May 30).
  
       
26   Important
      drug safety information: Celebrex (Dear Healthcare Professional
      Letter).  
Mississauga (ON): Pharmacia Canada Inc.; 2002 May 13. Available: 
      www.hc-sc.gc.ca/hpb-dgps/therapeut/zfiles/english/industry/celebrex_e.html 
      (accessed 2002 May 30).
  
       
27   Konstam
      MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ. 
      Cardiovascular thrombotic events in controlled clinical trials of rofecoxib.  
Circulation 2001; 104: 2280-2288.
  
       
28   Whitcomb
      DC, Block GD.  
Association of acetaminophen hepatoxicity with fasting and ethanol use.  
Journal of the American Medical Association 1994;
      272(23): 1845-1850.
  
       
29   Cherkin
      DW, Dyer S, Browne W, Townsend J. Frank AO.  
Medication use for low back pain in primary care.  
Spine 1998; 23: 607-14.
  
       
30   Rome
      PL.  
Perspectives: An Overview of Comparative Considerations of Cerebrovascular Accidents 
Chiropractic Journal of Australia 1999; 29 (3): 87—102
  
       
31   Sackett
      DL.  
Editorial: Evidence-Based Medicine.  
Spine 1998; 23(10):
      1085-1086.
  
       
32   Jonas
      W.  
The Evidence House: How to Build an Inclusive 
Base for Complementary Medicine 
Western Journal of Medicine 2001 2001 (Aug); 175 (2): 79–80
  
       
33   Caspi
      O, Millen C, Sechrest L.  
Integrity and research: Introducing the concept of dual blindness: How blind are double-blind clinical trials in
      alternative medicine?  
Alternative Therapies in Health and Medicine
      2000; 6(6): 493-498.
  
       
34   Koes BW, van Tulder MW, Ostelo R, Kim Burton A, Waddell G.   
Clinical Guidelines for the Management of Low Back Pain 
in Primary Care: An International Comparison 
Spine (Phila Pa 1976) 2001 (Nov 15); 26 (22): 2504–2513 
  
       
35   van
      Tulder MW, Koes BW, Bouter LM.  
Conservative treatment of acute and chronic nonspecific low back pain: A systematic review of randomized controlled
      trials of the most common interventions.  
Spine 22(18): 2128-2156,
      1997.
  
       
36   Feinstein
      AR.  
Meta-analysis: Statistical alchemy for the 21st century.  
Journal of
      Clinical Epidemiology 1995; 48(1): 71-79.
  
       
37   Balk
      EM, Bonis PAL, Moskowitz H, Schmid CH, Ioannidis JPA, Wang C, Lau J. 
      Correlation of quality measures with estimates of treatment effect in meta-analyses of randomized controlled trials.  
Journal of the American
      Medical Association 2002; 287(22): 2973-2982.
  
       
38   Juni
      P, Witsch A, Bloch R, Egger M.  
The hazards of scoring the quality of clinical trials for meta-analysis.  
Journal of the American Medical
      Association 1999; 282(11): 1054-1060.
  
       
39   Terrett
      AGJ.  
Current concepts in vertebrobasilar complications following spinal manipulation.  
West Des Moines, IA: NCMIC Group Inc., 2001.
  
       
40     Terrett AGJ:  
Misuse of the Literature by Medical Authors in Discussing Spinal Manipulative Therapy Injury  
J Manipulative Physiol Ther 1995 (May);   18 (4):   203–210 
  
       
41   Gatterman
      MI, Cooperstein R, Lantz C, Perle SM, Schneider MJ.  
Rating specific chiropractic technique procedures for common low back conditions.  
Journal
      of Manipulative and Physiological Therapeutics 2001; 24(7): 449-456.
  
       
42   Cooperstein
      RL, Perle SM, Gatterman MI, Lantz C, Schneider MJ.  
Chiropractic technique procedures for specific low back conditions: Characterizing the
      literature.  
Journal of Manipulative and Physiological Therapeutics
      2001; 24(6): 407-424.
  
       
43   Croft
      PR, Macfarlane GJ, Papageorgiou AC, Thomas E, Silman AJ.  
Outcome of low back pain in general practice: 
A prospective study  
BMJ 1998 (May 2); 316 (7141): 1356–1359
  
       
44   McGorry
      RW, Webster BS, Snook SH, Hsiang SM.  
The relation between pain intensity, disability, and the episodic nature of chronic and recurrent low back
      pain.  
Spine 2000; 25(7): 834-841.
  
       
45   Hestbaek
      L, Leboeuf-Yde C, Engberg M, Lauritzen T, Bruun stat NH.  
LBP: What is the long-term course?  
European Spine Journal 2003; 12(2): 149-165.
  
       
46   
 Smith M, Stano M.  
Costs and Recurrences of Chiropractic and Medical Episodes of Low-back Care  
Journal of Manipulative and Physiological Therapeutics 1997 (Jan);   20 (1):   5–12
  
       
47  Koes BW, Bouter LM, van Mameren H, et al.  
Randomised Clinical Trial of Manipulative Therapy and Physiotherapy 
for Persistent Back and Neck Complaints: Results of 
One Year Follow Up  
British Medical Journal 1992 (Mar 7); 304 (6827): 601–605
  
       
48   Skargren
      EI, Oberg BE, Carlsson PG, Gade M.  
Cost and effectiveness analysis of chiropractic and physiotherapy treatment for low back and neck pain.  
Spine
      1997; 22: 2167-2177.
  
       
49   
Meade TW, Dyer S, Browne W, et al:  
Randomised Comparison of Chiropractic and Hospital Outpatient 
Management for Low Back Pain: Results from Extended Follow up 
British Medical Journal 1995 (Aug 5); 311 (7001): 349–351 
  
       
50   Meade TW, Dyer S, Browne W, et al:  
Randomised Comparison of Chiropractic and Hospital Outpatient Management for Low Back Pain: 
Results from Extended Follow up 
British Medical Journal 1995 (Aug 5);   311 (7001):   349–351
  
       
51   Boline, PD, Kassak, K, Bronfort, G, Nelson, C, and Anderson, AV.  
Spinal Manipulation vs. Amitriptyline for the Treatment of Chronic Tension-type Headaches: 
A Randomized Clinical Trial   
J Manipulative Physiol Ther 1995 (Mar);   18 (3):   148–154
  
       
52   Nelson
Nelson CF, Bronfort G, Evans R, Boline P, Goldsmith C, Anderson AV:  
The Efficacy of Spinal Manipulation, Amitriptyline and the Combination of Both Therapies 
for the Prophylaxis of Migraine Headache  
J Manipulative Physiol Ther 1998 (Oct);    21 (8):    511–519
  
       
53   Tonelli
      MR.  
The philosophical limits of evidence-based medicine.  
Academic Medicine 1998; 73(12): 1234-1240.
  
       
54   Horwitz RI.  
The dark side of evidence-based medicine.  
Cleveland Clinic Journal of Medicine 1996; 63: 320-323.
  
 
Return to LOW BACK PAIN
 |